Credit Suisse Ag Incyte Corp Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Incyte Corp stock. As of the latest transaction made, Credit Suisse Ag holds 742,187 shares of INCY stock, worth $49.1 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

742,187

Previous 741,602 0.08%

Holding current value

$49.1 Million

Previous $46.6 Million 9.2%

% of portfolio

0.04%

Previous 0.05%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$56.55 - $66.59 $33,081 - $38,955	585 Added 0.08%	742,187 $42.3 Million
Q4 2023 Feb 08, 2024	BUY	$52.16 - $64.19 $257,253 - $316,585	4,932 Added 0.67%	741,602 $46.6 Million
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $3.37 Million - $3.84 Million	58,276 Added 8.59%	736,670 $42.6 Million
Q2 2023 Aug 11, 2023	SELL	$60.95 - $75.51 $20.4 Million - $25.3 Million	-335,301 Reduced 33.08%	678,394 $42.2 Million
Q1 2023 May 10, 2023	SELL	$70.23 - $86.01 $1.04 Million - $1.27 Million	-14,801 Reduced 1.44%	1,013,695 $73.3 Million
Q4 2022 Feb 13, 2023	BUY	$67.18 - $84.11 $35.9 Million - $45 Million	535,029 Added 108.42%	1,028,496 $82.6 Million
Q3 2022 Nov 10, 2022	SELL	$66.18 - $82.86 $23.2 Million - $29 Million	-349,905 Reduced 41.49%	493,467 $32.9 Million
Q2 2022 Aug 12, 2022	BUY	$66.18 - $83.18 $26.4 Million - $33.2 Million	399,052 Added 89.81%	843,372 $64.1 Million
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $1.05 Million - $1.26 Million	15,830 Added 3.69%	444,320 $35.3 Million
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $7.56 Million - $8.85 Million	119,426 Added 38.64%	428,490 $31.5 Million
Q3 2021 Nov 12, 2021	SELL	$68.67 - $84.02 $93,116 - $113,931	-1,356 Reduced 0.44%	309,064 $21.3 Million
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $8.03 Million - $8.8 Million	-100,506 Reduced 24.46%	310,420 $26.1 Million
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $566,729 - $749,227	-7,455 Reduced 1.78%	410,926 $33.4 Million
Q4 2020 Feb 12, 2021	BUY	$80.74 - $97.7 $8.73 Million - $10.6 Million	108,185 Added 34.88%	418,381 $36.4 Million
Q3 2020 Nov 13, 2020	SELL	$85.07 - $109.69 $15.8 Million - $20.3 Million	-185,354 Reduced 37.4%	310,196 $27.8 Million
Q2 2020 Aug 12, 2020	BUY	$74.18 - $108.93 $15.5 Million - $22.8 Million	208,889 Added 72.87%	495,550 $51.5 Million
Q1 2020 May 13, 2020	SELL	$63.18 - $85.97 $14.5 Million - $19.7 Million	-228,817 Reduced 44.39%	286,661 $21 Million
Q4 2019 Feb 12, 2020	BUY	$73.04 - $95.72 $18.5 Million - $24.3 Million	253,907 Added 97.07%	515,478 $45 Million
Q3 2019 Nov 12, 2019	SELL	$72.82 - $86.52 $715,820 - $850,491	-9,830 Reduced 3.62%	261,571 $19.4 Million
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $1.41 Million - $1.71 Million	19,229 Added 7.63%	271,401 $23.1 Million
Q1 2019 May 14, 2019	SELL	$63.56 - $88.17 $218,265 - $302,775	-3,434 Reduced 1.34%	252,172 $21.7 Million
Q4 2018 Feb 13, 2019	SELL	$58.5 - $69.94 $2.51 Million - $3 Million	-42,865 Reduced 14.36%	255,606 $16.3 Million
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $711,483 - $855,278	11,522 Added 4.02%	298,471 $20.6 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $17.3 Million - $23.9 Million	-285,027 Reduced 49.83%	286,949 $19.2 Million
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $1.41 Million - $1.71 Million	16,917 Added 3.05%	571,976 $47.7 Million
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $8.4 Million - $10.5 Million	89,760 Added 19.29%	555,059 $52.6 Million
Q3 2017 Nov 14, 2017	SELL	$109.15 - $138.27 $15 Million - $19 Million	-137,559 Reduced 22.82%	465,299 $54.3 Million
Q2 2017 Aug 14, 2017	BUY	N/A	602,858	602,858 $75.9 Million

Others Institutions Holding INCY

# of Institutions

629

Shares Held

198M

Call Options Held

766K

Put Options Held

476K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $14.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account